# A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

> **NCT02265237** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 184 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT02265237
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2016-07-28
- **Final completion:** 2017-04-07
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2017-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265237, "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02265237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*